Back to results

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT)

Primary Purpose

Acute Decompensated Heart Failure, Congestive Heart Failure

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Aliskiren

Placebo

About this trial

This is an interventional treatment trial for Acute Decompensated Heart Failure focused on measuring elevated BNP, reduced LVEF, Acute Heart Failure, Cardiovascular death, CHF, hospitalization, morbi-mortality trial, outcome study, endpoint driven, plasma renin activity, renin angiotensin, aldosterone system, direct renin inhibitors, BNP, KCCQ, eGFR

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

Patient hospitalized with a primary diagnosis of worsening heart failure ≥ 18 years of age, male or female.
Patients with a diagnosis of acute heart failure expressed by symptoms (dyspnea or fatigability - NYHA Class III-IV) and signs of fluid overload (i.e., jugular venous distension, edema or positive rales auscultation or pulmonary congestion on chest x-ray) at the time of hospitalization.
- LVEF < 40% (measured within the last 6 months).
- Hospitalization for ADHF and remain "stabilized" for at least 6 hours (defined as SBP ≥ 110 mm Hg after acute decompensated episode) and did not receive IV vasodilators (other than nitrates) and/or IV inotropic drugs at anytime from ADHF presentation to time of randomization.
Elevated BNP at Visit 1 or at randomization (BNP ≥ 400 pg/ml).
Patients with a history of chronic heart failure on standard therapy defined as requiring HF treatment for at least 30 days before the current hospitalization (NYHA Class II - IV).

Exclusion Criteria:

Patients that required any use of IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for worsening HF to randomization.
Concomitant use of ACEI and ARB at randomization.
Right heart failure due to pulmonary disease.
Diagnosis of postpartum cardiomyopathy.
Myocardial infarction or cardiac surgery, including percutaneous transluminal coronary angioplasty (PTCA), within past 3 months.
Patients with a history of heart transplant or who are on a transplant list.
Unstable angina or coronary artery disease likely to require coronary artery bypass graft (CABG) or PTCA before randomization.

Other protocol-defined inclusion/exclusion criteria applied.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Aliskiren

Placebo

Arm Description

Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.

Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.

Outcomes

Primary Outcome Measures

Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6 Months

Time to first confirmed occurrence of either cardiovascular death or heart failure re-hospitalization within 6 months of randomization was the primary efficacy variable. For the primary efficacy analysis, an event will be considered for the analysis if it occurs on or before Day 190 (189 days from randomization). The primary composite endpoint is the the composite of cardiovascular death or heart faliure re-hospitalization within 6 months.

Secondary Outcome Measures

Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 12 Months

Time to first confirmed occurrence of either cardiovascular death or heart failure re-hospitalization within 12 months of randomization was the key secondary efficacy variable. For the primary efficacy analysis, an event will be considered for the analysis if it occurs on or before Day 395 (394 days from randomization). The secondary composite endpoint is the the composite of cardiovascular death or heart faliure re-hospitalization within 12 months.

Change From Baseline in the Clinical Summary Score to 1 Month, 6 Months and 12 Months

Symptom reduction and reduction in physical limitations was assessed using the clinical summary score of the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is a self-administered questionnaire and contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Health-Related Quality of Life (QoL), including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Each scale score was calculated as the mean of its item scores and transformed to a 0-100 scale, with higher score indicating higher level of functioning. A score of 100 represents perfect health whereas a score of 0 represents death. A positive change in score from baseline indicates an improvement.

Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 6 Months

A cardiovascular event defined as CV death, heart faliure re-hospitalization, non-fatal myocardial infarction (MI), nonfatal stroke, sudden death with resuscitation.

Time to Event Analysis: Number of Patients With All-cause Mortality Hospitalized for an AHF Event Within 12 Months

Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Level at 1 Month, 6 Months, and 12 Months

The reported Least square means, and Confidential Interval were from a repeated measures model on log transformed NT-proBNP data containing treatment, visit, and region as factors, log baseline NT-proBNP as a continuous covariate and treatment by visit and visit by log baseline NT-proBNP as interaction terms.

Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 12 Months

A cardiovascular event defined as CV death, heart faliure re-hospitalization, non-fatal myocardial infarction (MI), nonfatal stroke, sudden death with resuscitation.

Full Information

NCT ID

NCT00894387

First Posted

May 5, 2009

Last Updated

October 15, 2013

Sponsor

Novartis Pharmaceuticals

1. Study Identification

Unique Protocol Identification Number

NCT00894387

Brief Title

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Acronym

ASTRONAUT

Official Title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure

Study Type

Interventional

2. Study Status

Record Verification Date

October 2013

Overall Recruitment Status

Completed

Study Start Date

May 2009 (undefined)

Primary Completion Date

August 2012 (Actual)

Study Completion Date

August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary

This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart failure (CHF) patients hospitalized for an episode of acute decompensated heart failure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Acute Decompensated Heart Failure, Congestive Heart Failure

Keywords

elevated BNP, reduced LVEF, Acute Heart Failure, Cardiovascular death, CHF, hospitalization, morbi-mortality trial, outcome study, endpoint driven, plasma renin activity, renin angiotensin, aldosterone system, direct renin inhibitors, BNP, KCCQ, eGFR

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

1639 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Aliskiren

Arm Type

Experimental

Arm Description

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.

Intervention Type

Drug

Intervention Name(s)

Aliskiren

Other Intervention Name(s)

Aliskiren®,, Tekturna®,, Rasilez®,, SPP100

Intervention Description

Aliskiren 150 mg and Aliskiren 300 mg

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Placebo

Primary Outcome Measure Information:

Title

Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6 Months

Description

Time Frame

6 months

Secondary Outcome Measure Information:

Title

Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 12 Months

Description

Time Frame

12 months

Title

Change From Baseline in the Clinical Summary Score to 1 Month, 6 Months and 12 Months

Description

Time Frame

Baseline, 1 months, 6 months and 12 months

Title

Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 6 Months

Description

A cardiovascular event defined as CV death, heart faliure re-hospitalization, non-fatal myocardial infarction (MI), nonfatal stroke, sudden death with resuscitation.

Time Frame

6 months

Title

Time to Event Analysis: Number of Patients With All-cause Mortality Hospitalized for an AHF Event Within 12 Months

Time Frame

12 months

Title

Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Level at 1 Month, 6 Months, and 12 Months

Description

Time Frame

Baseline, 1 month, 6 months and 12 months

Title

Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 12 Months

Description

A cardiovascular event defined as CV death, heart faliure re-hospitalization, non-fatal myocardial infarction (MI), nonfatal stroke, sudden death with resuscitation.

Time Frame

12 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion criteria: Patient hospitalized with a primary diagnosis of worsening heart failure ≥ 18 years of age, male or female. Patients with a diagnosis of acute heart failure expressed by symptoms (dyspnea or fatigability - NYHA Class III-IV) and signs of fluid overload (i.e., jugular venous distension, edema or positive rales auscultation or pulmonary congestion on chest x-ray) at the time of hospitalization. LVEF < 40% (measured within the last 6 months). Hospitalization for ADHF and remain "stabilized" for at least 6 hours (defined as SBP ≥ 110 mm Hg after acute decompensated episode) and did not receive IV vasodilators (other than nitrates) and/or IV inotropic drugs at anytime from ADHF presentation to time of randomization. Elevated BNP at Visit 1 or at randomization (BNP ≥ 400 pg/ml). Patients with a history of chronic heart failure on standard therapy defined as requiring HF treatment for at least 30 days before the current hospitalization (NYHA Class II - IV). Exclusion Criteria: Patients that required any use of IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for worsening HF to randomization. Concomitant use of ACEI and ARB at randomization. Right heart failure due to pulmonary disease. Diagnosis of postpartum cardiomyopathy. Myocardial infarction or cardiac surgery, including percutaneous transluminal coronary angioplasty (PTCA), within past 3 months. Patients with a history of heart transplant or who are on a transplant list. Unstable angina or coronary artery disease likely to require coronary artery bypass graft (CABG) or PTCA before randomization. Other protocol-defined inclusion/exclusion criteria applied.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Novartis Pharmaceuticals

Organizational Affiliation

Novartis Pharmaceuticals

Official's Role

Study Director

First Name & Middle Initial & Last Name & Degree

Novartis

Organizational Affiliation

Novartis

Official's Role

Study Director

Facility Information:

Facility Name

Novartis Investigative Site

City

Mobile

State/Province

Alabama

ZIP/Postal Code

36608

Country

United States

Facility Name

Novartis Investigative Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85723-0001

Country

United States

Facility Name

Novartis Investigative Site

City

Los Angeles

State/Province

California

ZIP/Postal Code

90073

Country

United States

Facility Name

Novartis Investigative Site

City

San Diego

State/Province

California

ZIP/Postal Code

92103

Country

United States

Facility Name

Novartis Investigative Site

City

Sylmar

State/Province

California

ZIP/Postal Code

91342

Country

United States

Facility Name

Novartis Investigative Site

City

Torrance

State/Province

California

ZIP/Postal Code

90502

Country

United States

Facility Name

Novartis Investigative Site

City

Hartford

State/Province

Connecticut

ZIP/Postal Code

06102-5037

Country

United States

Facility Name

Novartis Investigative Site

City

Washington

State/Province

District of Columbia

ZIP/Postal Code

20010-2975

Country

United States

Facility Name

Novartis Investigative Site

City

Washington

State/Province

District of Columbia

ZIP/Postal Code

20037

Country

United States

Facility Name

Novartis Investigative Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32207

Country

United States

Facility Name

Novartis Investigative Site

City

Macon

State/Province

Georgia

ZIP/Postal Code

31201

Country

United States

Facility Name

Novartis Investigative Site

City

Oakbrook Terrace

State/Province

Illinois

ZIP/Postal Code

60181

Country

United States

Facility Name

Novartis Investigative Site

City

Iowa City

State/Province

Iowa

ZIP/Postal Code

52245

Country

United States

Facility Name

Novartis Investigative Site

City

Lafayette

State/Province

Louisiana

ZIP/Postal Code

70501

Country

United States

Facility Name

Novartis Investigative Site

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48202

Country

United States

Facility Name

Novartis Investigative Site

City

Kalamazoo

State/Province

Michigan

ZIP/Postal Code

49048

Country

United States

Facility Name

Novartis Investigative Site

City

St. Louis

State/Province

Missouri

ZIP/Postal Code

63110

Country

United States

Facility Name

Novartis Investigative Site

City

Cherry Hill

State/Province

New Jersey

ZIP/Postal Code

08034

Country

United States

Facility Name

Novartis Investigative Site

City

Newark

State/Province

New Jersey

ZIP/Postal Code

07103-2714

Country

United States

Facility Name

Novartis Investigative Site

City

Bronx

State/Province

New York

ZIP/Postal Code

10461

Country

United States

Facility Name

Novartis Investigative Site

City

Buffalo

State/Province

New York

ZIP/Postal Code

14203

Country

United States

Facility Name

Novartis Investigative Site

City

Buffalo

State/Province

New York

ZIP/Postal Code

14215

Country

United States

Facility Name

Novartis Investigative Site

City

Saratoga Springs

State/Province

New York

ZIP/Postal Code

12866

Country

United States

Facility Name

Novartis Investigative Site

City

Chapel Hill

State/Province

North Carolina

ZIP/Postal Code

27599-7075

Country

United States

Facility Name

Novartis Investigative Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45219

Country

United States

Facility Name

Novartis Investigative Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45267-0585

Country

United States

Facility Name

Novartis Investigative Site

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44109-1998

Country

United States

Facility Name

Novartis Investigative Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19102-1192

Country

United States

Facility Name

Novartis Investigative Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19140

Country

United States

Facility Name

Novartis Investigative Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15212

Country

United States

Facility Name

Novartis Investigative Site

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29403

Country

United States

Facility Name

Novartis Investigative Site

City

Rapid City

State/Province

South Dakota

ZIP/Postal Code

57701

Country

United States

Facility Name

Novartis Investigative Site

City

Springfield

State/Province

Tennessee

ZIP/Postal Code

37172

Country

United States

Facility Name

Novartis Investigative Site

City

Brownsville

State/Province

Texas

ZIP/Postal Code

78520

Country

United States

Facility Name

Novartis Investigative Site

City

Charlottesville

State/Province

Virginia

ZIP/Postal Code

22908

Country

United States

Facility Name

Novartis Investigative Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23249

Country

United States

Facility Name

Novartis Investigative Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23298

Country

United States

Facility Name

Novartis Investigative Site

City

San Nicolas

State/Province

Buenos Aires

ZIP/Postal Code

B2900IIC

Country

Argentina

Facility Name

Novartis Investigative Site

City

Posadas

State/Province

Misiones

ZIP/Postal Code

N3300AHX

Country

Argentina

Facility Name

Novartis Investigative Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

S2000DSV

Country

Argentina

Facility Name

Novartis Investigative Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

S2001ODA

Country

Argentina

Facility Name

Novartis Investigative Site

City

San Miguel de Tucuman

State/Province

Tucuman

ZIP/Postal Code

T4000JCU

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

B1650CSQ

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

B1708KCH

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

C1050AAK

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

C1094AAD

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

C1201AAO

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos aires

ZIP/Postal Code

C1210AAP

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

C1428AQK

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

ZIP/Postal Code

W3400ABH

Country

Argentina

Facility Name

Novartis Investigative Site

City

Buenos Aires

Country

Argentina

Facility Name

Novartis Investigative Site

City

Cordoba

ZIP/Postal Code

X5000AAI

Country

Argentina

Facility Name

Novartis Investigative Site

City

Cordoba

ZIP/Postal Code

X5006IKK

Country

Argentina

Facility Name

Novartis Investigative Site

City

Corrientes

ZIP/Postal Code

3400

Country

Argentina

Facility Name

Novartis Investigative Site

City

Corrientes

ZIP/Postal Code

W3400CBI

Country

Argentina

Facility Name

Novartis Investigative Site

City

Corrientes

ZIP/Postal Code

W3400

Country

Argentina

Facility Name

Novartis Investigative Site

City

Quilmes

ZIP/Postal Code

1878

Country

Argentina

Facility Name

Novartis Investigative Site

City

Santa Fe

ZIP/Postal Code

3000

Country

Argentina

Facility Name

Novartis Investigative Site

City

Santa Fe

ZIP/Postal Code

S2004CMW

Country

Argentina

Facility Name

Novartis Investigative Site

City

Tucuman

ZIP/Postal Code

T4000NIJ

Country

Argentina

Facility Name

Novartis Investigative Site

City

Antwerpen

ZIP/Postal Code

2020

Country

Belgium

Facility Name

Novartis Investigative Site

City

Brasschaat

ZIP/Postal Code

2930

Country

Belgium

Facility Name

Novartis Investigative Site

City

Genk

ZIP/Postal Code

3600

Country

Belgium

Facility Name

Novartis Investigative Site

City

Gent

ZIP/Postal Code

9000

Country

Belgium

Facility Name

Novartis Investigative Site

City

Hasselt

ZIP/Postal Code

3500

Country

Belgium

Facility Name

Novartis Investigative Site

City

Huy

ZIP/Postal Code

4500

Country

Belgium

Facility Name

Novartis Investigative Site

City

Leuven

ZIP/Postal Code

3000

Country

Belgium

Facility Name

Novartis Investigative Site

City

Mechelen

ZIP/Postal Code

2800

Country

Belgium

Facility Name

Novartis Investigative Site

City

Mol

ZIP/Postal Code

2400

Country

Belgium

Facility Name

Novartis Investigative Site

City

Namur

ZIP/Postal Code

5000

Country

Belgium

Facility Name

Novartis Investigative Site

City

Belo Horizonte

State/Province

ZIP/Postal Code

20180-090

Country

Brazil

Facility Name

Novartis Investigative Site

City

Belo Horizonte

State/Province

ZIP/Postal Code

30150-221

Country

Brazil

Facility Name

Novartis Investigative Site

City

Belo Horizonte

State/Province

Country

Brazil

Facility Name

Novartis Investigative Site

City

Londrina

State/Province

ZIP/Postal Code

86051-990

Country

Brazil

Facility Name

Novartis Investigative Site

City

Rio de Janeiro

State/Province

ZIP/Postal Code

22261-010

Country

Brazil

Facility Name

Novartis Investigative Site

City

Porto Alegre

State/Province

ZIP/Postal Code

90610-000

Country

Brazil

Facility Name

Novartis Investigative Site

City

Campinas

State/Province

ZIP/Postal Code

13060-904

Country

Brazil

Facility Name

Novartis Investigative Site

City

Sao Jose do Rio Preto

State/Province

ZIP/Postal Code

15150-210

Country

Brazil

Facility Name

Novartis Investigative Site

City

São Paulo

State/Province

ZIP/Postal Code

05403-000

Country

Brazil

Facility Name

Novartis Investigative Site

City

St. John's

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1B 3V6

Country

Canada

Facility Name

Novartis Investigative Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 2Y9

Country

Canada

Facility Name

Novartis Investigative Site

City

Ottawa

State/Province

Ontario

ZIP/Postal Code

K1Y 4W7

Country

Canada

Facility Name

Novartis Investigative Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5B 1W8

Country

Canada

Facility Name

Novartis Investigative Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H3A 1A1

Country

Canada

Facility Name

Novartis Investigative Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H3T 1E2

Country

Canada

Facility Name

Novartis Investigative Site

City

Barranquilla

State/Province

Atlantico

Country

Colombia

Facility Name

Novartis Investigative Site

City

Bogotá

State/Province

Cundinamarca

Country

Colombia

Facility Name

Novartis Investigative Site

City

Barranquilla

Country

Colombia

Facility Name

Novartis Investigative Site

City

Bogotá

ZIP/Postal Code

0000

Country

Colombia

Facility Name

Novartis Investigative Site

City

Bogotá

Country

Colombia

Facility Name

Novartis Investigative Site

City

Cali

Country

Colombia

Facility Name

Novartis Investigative Site

City

Florida Blanca

Country

Colombia

Facility Name

Novartis Investigative Site

City

Hradec Kralove

State/Province

CZE

ZIP/Postal Code

500 05

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Brno - Bohunice

ZIP/Postal Code

625 00

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Brno

ZIP/Postal Code

636 00

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Olomouc

ZIP/Postal Code

775 20

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Prague 4

ZIP/Postal Code

146 24

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Prague 5

ZIP/Postal Code

150 00

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Praha 10

ZIP/Postal Code

100 34

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Praha 2

ZIP/Postal Code

128 08

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Slany

ZIP/Postal Code

27401

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Teplice

ZIP/Postal Code

415 29

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Znojmo

ZIP/Postal Code

669 02

Country

Czech Republic

Facility Name

Novartis Investigative Site

City

Jyvaskyla

ZIP/Postal Code

FIN-40620

Country

Finland

Facility Name

Novartis Investigative Site

City

Turku

ZIP/Postal Code

20520

Country

Finland

Facility Name

Novartis Investigative Site

City

Bordeaux Cedex

ZIP/Postal Code

33075

Country

France

Facility Name

Novartis Investigative Site

City

Grenoble

ZIP/Postal Code

38043

Country

France

Facility Name

Novartis Investigative Site

City

Le Chesnay

Country

France

Facility Name

Novartis Investigative Site

City

Paris

ZIP/Postal Code

75013

Country

France

Facility Name

Novartis Investigative Site

City

Paris

ZIP/Postal Code

75571

Country

France

Facility Name

Novartis Investigative Site

City

Pessac Cedex

ZIP/Postal Code

33604

Country

France

Facility Name

Novartis Investigative Site

City

Pontoise

ZIP/Postal Code

F-95300

Country

France

Facility Name

Novartis Investigative Site

City

Toulouse Cedex

ZIP/Postal Code

31059

Country

France

Facility Name

Novartis Investigative Site

City

Augsburg

ZIP/Postal Code

86156

Country

Germany

Facility Name

Novartis Investigative Site

City

Bad Bevensen

ZIP/Postal Code

29549

Country

Germany

Facility Name

Novartis Investigative Site

City

Bad Nauheim

ZIP/Postal Code

61231

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

10098

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

10249

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

12621

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

13347

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

13353

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

13578

Country

Germany

Facility Name

Novartis Investigative Site

City

Bischofswerda

ZIP/Postal Code

01877

Country

Germany

Facility Name

Novartis Investigative Site

City

Bonn

ZIP/Postal Code

53105

Country

Germany

Facility Name

Novartis Investigative Site

City

Bremen

ZIP/Postal Code

28277

Country

Germany

Facility Name

Novartis Investigative Site

City

Cloppenburg

ZIP/Postal Code

49661

Country

Germany

Facility Name

Novartis Investigative Site

City

Cottbus

ZIP/Postal Code

03048

Country

Germany

Facility Name

Novartis Investigative Site

City

Dessau

ZIP/Postal Code

D-06822

Country

Germany

Facility Name

Novartis Investigative Site

City

Detmold

ZIP/Postal Code

32756

Country

Germany

Facility Name

Novartis Investigative Site

City

Dortmund

ZIP/Postal Code

44137

Country

Germany

Facility Name

Novartis Investigative Site

City

Dresden

ZIP/Postal Code

01067

Country

Germany

Facility Name

Novartis Investigative Site

City

Frankfurt

ZIP/Postal Code

60316

Country

Germany

Facility Name

Novartis Investigative Site

City

Frankfurt

ZIP/Postal Code

60488

Country

Germany

Facility Name

Novartis Investigative Site

City

Greifswald

ZIP/Postal Code

17475

Country

Germany

Facility Name

Novartis Investigative Site

City

Halle/'Saale

ZIP/Postal Code

06120

Country

Germany

Facility Name

Novartis Investigative Site

City

Hamburg

ZIP/Postal Code

20246

Country

Germany

Facility Name

Novartis Investigative Site

City

Herne

ZIP/Postal Code

44649

Country

Germany

Facility Name

Novartis Investigative Site

City

Herrsching

ZIP/Postal Code

82211

Country

Germany

Facility Name

Novartis Investigative Site

City

Jena

ZIP/Postal Code

07740

Country

Germany

Facility Name

Novartis Investigative Site

City

Konstanz

ZIP/Postal Code

78464

Country

Germany

Facility Name

Novartis Investigative Site

City

Köln

ZIP/Postal Code

50924

Country

Germany

Facility Name

Novartis Investigative Site

City

Langen

ZIP/Postal Code

63225

Country

Germany

Facility Name

Novartis Investigative Site

City

Ludwigslust

ZIP/Postal Code

19288

Country

Germany

Facility Name

Novartis Investigative Site

City

Magdeburg

ZIP/Postal Code

39120

Country

Germany

Facility Name

Novartis Investigative Site

City

Merseburg

ZIP/Postal Code

06217

Country

Germany

Facility Name

Novartis Investigative Site

City

Muenchen

ZIP/Postal Code

81377

Country

Germany

Facility Name

Novartis Investigative Site

City

Nordhorn

ZIP/Postal Code

48527

Country

Germany

Facility Name

Novartis Investigative Site

City

Paderborn

ZIP/Postal Code

33098

Country

Germany

Facility Name

Novartis Investigative Site

City

Quedlinburg

ZIP/Postal Code

06484

Country

Germany

Facility Name

Novartis Investigative Site

City

Regensburg

ZIP/Postal Code

93053

Country

Germany

Facility Name

Novartis Investigative Site

City

Rostock

ZIP/Postal Code

18057

Country

Germany

Facility Name

Novartis Investigative Site

City

Sömmerda

ZIP/Postal Code

99610

Country

Germany

Facility Name

Novartis Investigative Site

City

Weiden

ZIP/Postal Code

92637

Country

Germany

Facility Name

Novartis Investigative Site

City

Pecs

State/Province

Baranya

ZIP/Postal Code

7621

Country

Hungary

Facility Name

Novartis Investigative Site

City

Balatonfured

ZIP/Postal Code

H-8231

Country

Hungary

Facility Name

Novartis Investigative Site

City

Budapest

ZIP/Postal Code

1027

Country

Hungary

Facility Name

Novartis Investigative Site

City

Budapest

ZIP/Postal Code

1096

Country

Hungary

Facility Name

Novartis Investigative Site

City

Budapest

ZIP/Postal Code

H-1106

Country

Hungary

Facility Name

Novartis Investigative Site

City

Hodmezovasarhely

ZIP/Postal Code

6800

Country

Hungary

Facility Name

Novartis Investigative Site

City

Nagykanizsa

ZIP/Postal Code

8800

Country

Hungary

Facility Name

Novartis Investigative Site

City

Szolnok

ZIP/Postal Code

H-5000

Country

Hungary

Facility Name

Novartis Investigative Site

City

Zalaegerszeg

ZIP/Postal Code

8900

Country

Hungary

Facility Name

Novartis Investigative Site

City

Secunderabad

State/Province

Andhra Pradesh

ZIP/Postal Code

500003

Country

India

Facility Name

Novartis Investigative Site

City

Vadodara

State/Province

Gujrat

ZIP/Postal Code

390015

Country

India

Facility Name

Novartis Investigative Site

City

Bangalore

State/Province

Karnataka

ZIP/Postal Code

560 069

Country

India

Facility Name

Novartis Investigative Site

City

Bangalore

State/Province

Karnataka

ZIP/Postal Code

560099

Country

India

Facility Name

Novartis Investigative Site

City

Mangalore

State/Province

Karnataka

ZIP/Postal Code

575002

Country

India

Facility Name

Novartis Investigative Site

City

Kochi

State/Province

Kerala

ZIP/Postal Code

682 026

Country

India

Facility Name

Novartis Investigative Site

City

Indore

State/Province

M.p.

ZIP/Postal Code

452001

Country

India

Facility Name

Novartis Investigative Site

City

Mumbai

State/Province

Maharashtra

ZIP/Postal Code

400 022

Country

India

Facility Name

Novartis Investigative Site

City

Nagpur

State/Province

Maharashtra

ZIP/Postal Code

440010

Country

India

Facility Name

Novartis Investigative Site

City

Nagpur

State/Province

Maharashtra

ZIP/Postal Code

440012

Country

India

Facility Name

Novartis Investigative Site

City

Pune

State/Province

Maharashtra

ZIP/Postal Code

411004

Country

India

Facility Name

Novartis Investigative Site

City

Pune

State/Province

Maharashtra

ZIP/Postal Code

411011

Country

India

Facility Name

Novartis Investigative Site

City

Pune

State/Province

Maharashtra

ZIP/Postal Code

411030

Country

India

Facility Name

Novartis Investigative Site

City

Coimbatore

State/Province

Tamil Nadu

ZIP/Postal Code

641014

Country

India

Facility Name

Novartis Investigative Site

City

Coimbatore

State/Province

Tamil Nadu

ZIP/Postal Code

641037

Country

India

Facility Name

Novartis Investigative Site

City

Bangalore

ZIP/Postal Code

560 034

Country

India

Facility Name

Novartis Investigative Site

City

Hyderabad

ZIP/Postal Code

500 063

Country

India

Facility Name

Novartis Investigative Site

City

New Delhi

ZIP/Postal Code

110 025

Country

India

Facility Name

Novartis Investigative Site

City

Ashkelon

ZIP/Postal Code

78278

Country

Israel

Facility Name

Novartis Investigative Site

City

Hadera

ZIP/Postal Code

38100

Country

Israel

Facility Name

Novartis Investigative Site

City

Haifa

ZIP/Postal Code

34362

Country

Israel

Facility Name

Novartis Investigative Site

City

Jerusalem

ZIP/Postal Code

91120

Country

Israel

Facility Name

Novartis Investigative Site

City

Nazareth

ZIP/Postal Code

16100

Country

Israel

Facility Name

Novartis Investigative Site

City

Safed

ZIP/Postal Code

13100

Country

Israel

Facility Name

Novartis Investigative Site

City

Tel-Aviv

ZIP/Postal Code

64239

Country

Israel

Facility Name

Novartis Investigative Site

City

Pavia

State/Province

(pv)

ZIP/Postal Code

27100

Country

Italy

Facility Name

Novartis Investigative Site

City

Verona

State/Province

(vr)

ZIP/Postal Code

37126

Country

Italy

Facility Name

Novartis Investigative Site

City

Bologna

State/Province

ZIP/Postal Code

40138

Country

Italy

Facility Name

Novartis Investigative Site

City

Brescia

State/Province

ZIP/Postal Code

25123

Country

Italy

Facility Name

Novartis Investigative Site

City

Cremona

State/Province

ZIP/Postal Code

26100

Country

Italy

Facility Name

Novartis Investigative Site

City

Catania

State/Province

ZIP/Postal Code

95123

Country

Italy

Facility Name

Novartis Investigative Site

City

Lagosanto

State/Province

ZIP/Postal Code

44023

Country

Italy

Facility Name

Novartis Investigative Site

City

Foggia

State/Province

ZIP/Postal Code

71100

Country

Italy

Facility Name

Novartis Investigative Site

City

Firenze

State/Province

ZIP/Postal Code

50141

Country

Italy

Facility Name

Novartis Investigative Site

City

Grosseto

State/Province

ZIP/Postal Code

58100

Country

Italy

Facility Name

Novartis Investigative Site

City

Pozzilli

State/Province

ZIP/Postal Code

86077

Country

Italy

Facility Name

Novartis Investigative Site

City

Casarano

State/Province

ZIP/Postal Code

73042

Country

Italy

Facility Name

Novartis Investigative Site

City

Lecce

State/Province

ZIP/Postal Code

73100

Country

Italy

Facility Name

Novartis Investigative Site

City

Scorrano

State/Province

ZIP/Postal Code

73020

Country

Italy

Facility Name

Novartis Investigative Site

City

Monza

State/Province

ZIP/Postal Code

20900

Country

Italy

Facility Name

Novartis Investigative Site

City

Legnano

State/Province

ZIP/Postal Code

20025

Country

Italy

Facility Name

Novartis Investigative Site

City

Milano

State/Province

ZIP/Postal Code

20157

Country

Italy

Facility Name

Novartis Investigative Site

City

Palermo

State/Province

ZIP/Postal Code

90146

Country

Italy

Facility Name

Novartis Investigative Site

City

Perugia

State/Province

ZIP/Postal Code

06129

Country

Italy

Facility Name

Novartis Investigative Site

City

Parma

State/Province

ZIP/Postal Code

43100

Country

Italy

Facility Name

Novartis Investigative Site

City

Albano Laziale

State/Province

ZIP/Postal Code

00041

Country

Italy

Facility Name

Novartis Investigative Site

City

Roma

State/Province

ZIP/Postal Code

00185

Country

Italy

Facility Name

Novartis Investigative Site

City

Roma

State/Province

ZIP/Postal Code

00189

Country

Italy

Facility Name

Novartis Investigative Site

City

Rimini

State/Province

ZIP/Postal Code

47900

Country

Italy

Facility Name

Novartis Investigative Site

City

Siena

State/Province

ZIP/Postal Code

53100

Country

Italy

Facility Name

Novartis Investigative Site

City

Legnago

State/Province

ZIP/Postal Code

37045

Country

Italy

Facility Name

Novartis Investigative Site

City

Quezon City

State/Province

Metro Manila

ZIP/Postal Code

1109

Country

Philippines

Facility Name

Novartis Investigative Site

City

Manila

ZIP/Postal Code

1000

Country

Philippines

Facility Name

Novartis Investigative Site

City

Quezon City

ZIP/Postal Code

1100

Country

Philippines

Facility Name

Novartis Investigative Site

City

Grodzisk Wielkopolski

ZIP/Postal Code

62-065

Country

Poland

Facility Name

Novartis Investigative Site

City

Klodzko

ZIP/Postal Code

57-300

Country

Poland

Facility Name

Novartis Investigative Site

City

Kraków

ZIP/Postal Code

31-531

Country

Poland

Facility Name

Novartis Investigative Site

City

Lublin

ZIP/Postal Code

20-954

Country

Poland

Facility Name

Novartis Investigative Site

City

Lódz

ZIP/Postal Code

91-347

Country

Poland

Facility Name

Novartis Investigative Site

City

Ruda Slaska

ZIP/Postal Code

41-703

Country

Poland

Facility Name

Novartis Investigative Site

City

Swidnica

ZIP/Postal Code

58-100

Country

Poland

Facility Name

Novartis Investigative Site

City

Szczecin

ZIP/Postal Code

70-111

Country

Poland

Facility Name

Novartis Investigative Site

City

Walbrzych

ZIP/Postal Code

58-309

Country

Poland

Facility Name

Novartis Investigative Site

City

Warszawa

ZIP/Postal Code

03-242

Country

Poland

Facility Name

Novartis Investigative Site

City

Warszawa

ZIP/Postal Code

04-628

Country

Poland

Facility Name

Novartis Investigative Site

City

Wroclaw

ZIP/Postal Code

50-367

Country

Poland

Facility Name

Novartis Investigative Site

City

Wroclaw

ZIP/Postal Code

50-981

Country

Poland

Facility Name

Novartis Investigative Site

City

Zabrze

ZIP/Postal Code

41-800

Country

Poland

Facility Name

Novartis Investigative Site

City

Zamosc

ZIP/Postal Code

22-400

Country

Poland

Facility Name

Novartis Investigative Site

City

Bucuresti

State/Province

District 1

ZIP/Postal Code

014461

Country

Romania

Facility Name

Novartis Investigative Site

City

Bucharest

ZIP/Postal Code

020125

Country

Romania

Facility Name

Novartis Investigative Site

City

Bucharest

ZIP/Postal Code

021659

Country

Romania

Facility Name

Novartis Investigative Site

City

Craiova

ZIP/Postal Code

200642

Country

Romania

Facility Name

Novartis Investigative Site

City

Timisoara

ZIP/Postal Code

300310

Country

Romania

Facility Name

Novartis Investigative Site

City

Tirgoviste

ZIP/Postal Code

130083

Country

Romania

Facility Name

Novartis Investigative Site

City

Lubertsi

ZIP/Postal Code

140006

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

109377

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

111539

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

115487

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

117198

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

119881

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

121552

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

127473

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

127644

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Nizhnii Novgorod

ZIP/Postal Code

603000

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

S.-Petersburg

ZIP/Postal Code

192242

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

S.-Petersburg

ZIP/Postal Code

195197

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

S.-Petersburg

ZIP/Postal Code

196247

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

S.-Petersburg

ZIP/Postal Code

198205

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saint Petersburg

ZIP/Postal Code

195067

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saint Petersburg

ZIP/Postal Code

199106

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saint-Petersburg

ZIP/Postal Code

193312

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saint-Petersburg

ZIP/Postal Code

197341

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saint-Petersburg

ZIP/Postal Code

198013

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Sankt-Peterburg

ZIP/Postal Code

197022

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saratov

ZIP/Postal Code

410012

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saratov

ZIP/Postal Code

410028

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

St.Petersburg

ZIP/Postal Code

193163

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Yaroslavl

ZIP/Postal Code

150003

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Singapore

ZIP/Postal Code

119074

Country

Singapore

Facility Name

Novartis Investigative Site

City

Singapore

ZIP/Postal Code

168752

Country

Singapore

Facility Name

Novartis Investigative Site

City

Singapore

ZIP/Postal Code

768825

Country

Singapore

Facility Name

Novartis Investigative Site

City

Liptovsky Mikulas

State/Province

Slovak Republic

ZIP/Postal Code

831 23

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Presov

State/Province

Slovak Republic

ZIP/Postal Code

081 81

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Bratislava

ZIP/Postal Code

813 69

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Bratislava

ZIP/Postal Code

833 48

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Komarno

ZIP/Postal Code

94575

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Kosice-Saca

ZIP/Postal Code

040 01

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Kosice

ZIP/Postal Code

040 01

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Levice

ZIP/Postal Code

934 01

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Lucenec

ZIP/Postal Code

984 39

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Martin

ZIP/Postal Code

036 59

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Nitra

ZIP/Postal Code

949 01

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Trnava

ZIP/Postal Code

917 75

Country

Slovakia

Facility Name

Novartis Investigative Site

City

Sanlúcar de Barrameda

State/Province

Andalucia

ZIP/Postal Code

11540

Country

Spain

Facility Name

Novartis Investigative Site

City

Villamartin

State/Province

Andalucia

ZIP/Postal Code

11650

Country

Spain

Facility Name

Novartis Investigative Site

City

Palma de Mallorca

State/Province

Baleares

ZIP/Postal Code

07010

Country

Spain

Facility Name

Novartis Investigative Site

City

Barcelona

State/Province

Cataluña

ZIP/Postal Code

08003

Country

Spain

Facility Name

Novartis Investigative Site

City

Valencia

State/Province

Comunidad Valenciana

ZIP/Postal Code

46014

Country

Spain

Facility Name

Novartis Investigative Site

City

Santiago de Compostela

State/Province

Galicia

ZIP/Postal Code

15706

Country

Spain

Facility Name

Novartis Investigative Site

City

Majadanonda

State/Province

Madrid

ZIP/Postal Code

28220

Country

Spain

Facility Name

Novartis Investigative Site

City

Pozuelo de Alarcón

State/Province

Madrid

ZIP/Postal Code

28223

Country

Spain

Facility Name

Novartis Investigative Site

City

Madrid

ZIP/Postal Code

28007

Country

Spain

Facility Name

Novartis Investigative Site

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

Novartis Investigative Site

City

Madrid

ZIP/Postal Code

28046

Country

Spain

Facility Name

Novartis Investigative Site

City

Göteborg

ZIP/Postal Code

416 85

Country

Sweden

Facility Name

Novartis Investigative Site

City

Stockholm

ZIP/Postal Code

118 83

Country

Sweden

Facility Name

Novartis Investigative Site

City

Stockholm

ZIP/Postal Code

141 86

Country

Sweden

Facility Name

Novartis Investigative Site

City

Stockholm

ZIP/Postal Code

182 88

Country

Sweden

Facility Name

Novartis Investigative Site

City

Kaohsiung

ZIP/Postal Code

807

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Keelung City

ZIP/Postal Code

20401

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Lin-Ko

ZIP/Postal Code

33305

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taichung

ZIP/Postal Code

40447

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taipei

ZIP/Postal Code

112

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taipei

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Ankara

ZIP/Postal Code

06500

Country

Turkey

Facility Name

Novartis Investigative Site

City

Atakum / Samsun

ZIP/Postal Code

55139

Country

Turkey

Facility Name

Novartis Investigative Site

City

Etlik / Ankara

ZIP/Postal Code

06018

Country

Turkey

Facility Name

Novartis Investigative Site

City

Istanbul

ZIP/Postal Code

34303

Country

Turkey

Facility Name

Novartis Investigative Site

City

Istanbul

ZIP/Postal Code

34304

Country

Turkey

Facility Name

Novartis Investigative Site

City

Izmir

ZIP/Postal Code

35040

Country

Turkey

Facility Name

Novartis Investigative Site

City

Izmir

ZIP/Postal Code

35340

Country

Turkey

Facility Name

Novartis Investigative Site

City

Kirikkale

ZIP/Postal Code

71100

Country

Turkey

Facility Name

Novartis Investigative Site

City

Kocaeli

ZIP/Postal Code

41380

Country

Turkey

Facility Name

Novartis Investigative Site

City

Sivas

ZIP/Postal Code

58140

Country

Turkey

Facility Name

Novartis Investigative Site

City

Talas / Kayseri

ZIP/Postal Code

38039

Country

Turkey

12. IPD Sharing Statement

Citations:

PubMed Identifier

29143416

Citation

Vaduganathan M, Cheema B, Cleveland E, Sankar K, Subacius H, Fonarow GC, Solomon SD, Lewis EF, Greene SJ, Maggioni AP, Bohm M, Zannad F, Butler J, Gheorghiade M. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. Eur J Heart Fail. 2018 Apr;20(4):677-686. doi: 10.1002/ejhf.973. Epub 2017 Nov 16.

Results Reference

derived

PubMed Identifier

29044915

Citation

Greene SJ, Butler J, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Bohm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 Feb;20(2):281-291. doi: 10.1002/ejhf.1019. Epub 2017 Oct 17.

Results Reference

derived

PubMed Identifier

28960673

Citation

Lund LH, Trochu JN, Meyns B, Caliskan K, Shaw S, Schmitto JD, Schibilsky D, Damme L, Heatley J, Gustafsson F. Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study. Eur J Heart Fail. 2018 Jan;20(1):152-160. doi: 10.1002/ejhf.975. Epub 2017 Sep 27.

Results Reference

derived

PubMed Identifier

23478743

Citation

Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum In: JAMA. 2013 Apr 10;309(14):1461.

Results Reference

derived

PubMed Identifier

21123186

Citation

Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Bohm M, Gimpelewicz C, Botha J, Moores S, Lewis EF, Rattunde H, Maggioni A; ASTRONAUT investigators and study coordinators. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail. 2011 Jan;13(1):100-6. doi: 10.1093/eurjhf/hfq209. Epub 2010 Nov 30.

Results Reference

derived

Learn more about this trial

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

We'll reach out to this number within 24 hrs

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT)

Acute Decompensated Heart Failure, Congestive Heart Failure

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial